About TUDORZA® PRESSAIR®

(aclidinium bromide inhalation powder)

Use twice a day for the maintenance treatment of COPD1

TUDORZA® PRESSAIR®is not indicated for the initial treatment of acute episodes of bronchospasm (i.e. rescue therapy).1

Why TUDORZA® PRESSAIR®?

TUDORZA PRESSAIR is an anticholinergic indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Note: TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (i.e. rescue therapy).1

Reassuring Dual Feedback

Prescribe with confidence. TUDORZA PRESSAIR is the only preloaded dry powder inhaler that provides reassuring feedback in two ways* each time patients inhale their dose correctly.1 

A “click” will sound when the patient is inhaling correctly

The control window changes from GREEN to RED when a patient has successfully inhaled the full dose

TUDORZA PRESSAIR inhaler with label

*Feedback mechanisms consist of visual cues (color-controlled window) and an audible “click.” Note: some people may not hear the "click." Use the control window to ensure you have inhaled correctly.

INDICATIONS AND USAGE

TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

  • TUDORZA PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients
  • TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (i.e. rescue therapy)
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of TUDORZA PRESSAIR. Additionally, inhaled medicines, including TUDORZA PRESSAIR, may cause paradoxical bronchospasm. If any of these occurs, treatment with TUDORZA PRESSAIR should be stopped and other treatments considered
  • TUDORZA PRESSAIR should be used with caution in patients with narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any worsening of glaucoma or worsening of urinary retention develop
  • The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA PRESSAIR vs placebo, respectively. In a long-term cardiovascular safety trial of up to 3 years, the adverse reactions (occurring at a rate of ≥2% and more common than placebo) were nausea, back pain, cough, hypertension, sinusitis, constipation, arthralgia, anemia, muscle spasms, cardiac failure congestive, cellulitis, and gastroesophageal reflux disease

Please also see the Full Prescribing Information, including Patient Information.

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact Covis Pharma at 877-411-2510 or at medinfoUS@covispharma.com, or FDA at 1-800-FDA-1088 or fda.gov/medwatch.

MORE IMPORTANT SAFETY INFORMATION

Who should not use TUDORZA PRESSAIR?
TUDORZA PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients

INDICATIONS AND USAGE

TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

  • TUDORZA PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients
  • TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (i.e. rescue therapy)
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of TUDORZA PRESSAIR. Additionally, inhaled medicines, including TUDORZA PRESSAIR, may cause paradoxical bronchospasm. If any of these occurs, treatment with TUDORZA PRESSAIR should be stopped and other treatments considered
  • TUDORZA PRESSAIR should be used with caution in patients with narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any worsening of glaucoma or worsening of urinary retention develop
  • The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA PRESSAIR vs placebo, respectively. In a long-term cardiovascular safety trial of up to 3 years, the adverse reactions (occurring at a rate of ≥2% and more common than placebo) were nausea, back pain, cough, hypertension, sinusitis, constipation, arthralgia, anemia, muscle spasms, cardiac failure congestive, cellulitis, and gastroesophageal reflux disease

Please also see the Full Prescribing Information, including Patient Information.

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact Covis Pharma at 877-411-2510 or at medinfoUS@covispharma.com, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

REFERENCES: 1. Tudorza® Pressair® (aclidinium bromide inhalation powder) [prescribing information]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; February, 2021.